Richard Peters leads the Global Rare Diseases Business Unit at Genzyme Corporation. Over the past seven years, he has served in prior roles at the company as Head of Global & U.S. Medical Affairs for the Genzyme Transplant & Oncology Division; Medical Officer for Sanofi Global Oncology; Strategy Development Officer for the U.S. Rare Disease Genzyme organization; and Deputy Head for the Genzyme Global Rare Diseases Division. His previous roles in industry include medical leadership roles at Onyx Pharmaceuticals and Amgen as well as CEO of Mednav, a venture capital-backed healthcare information technology start-up. He also has served on the clinical staff at Massachusetts General Hospital in Boston. Richard began his medical training at the Université Catholique de Louvain in Brussels, Belgium. After immigrating to the United States, he earned his M.D. and Ph.D. in Pharmacology from the Medical University of South Carolina, completed postgraduate training at Massachusetts General Hospital and held a Howard Hughes Medical Institute Fellowship at Harvard Medical School. He has also served as a consulting editor for JAMA and as a contributing editor for Science, and has authored over 120 research articles and editorials.
In addition to serving as a scientific advisor for Aura, he serves on the boards of directors of X4 Pharmaceuticals, the Massachusetts Outdoor Heritage Foundation and Mint for Mounts.